Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model | Zendy

Cécile Vinot | Zendy; JeanMarc Tréluyer | Zendy; Carole Giraud | Zendy; Laurent Gavard | Zendy; Gilles Peytavin | Zendy; Laurent Mandelbrot | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model

Author(s) -

Cécile Vinot,

JeanMarc Tréluyer,

Carole Giraud,

Laurent Gavard,

Gilles Peytavin,

Laurent Mandelbrot

Publication year - 2016

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.00007-16

Subject(s) - raltegravir , fetus , perfusion , medicine , chemistry , endocrinology , pregnancy , biology , human immunodeficiency virus (hiv) , antiretroviral therapy , immunology , viral load , genetics

Placental transfer of the HIV integrase inhibitor raltegravir (RLT) was investigated in term human cotyledons in the maternal-to-fetal (n = 3) and fetal-to-maternal (n = 6) directions. In the maternal-to-fetal direction, the mean ± standard deviation (SD) fetal transfer rate (FTR) was 9.1% ± 1.4%, and the mean ± SD clearance index (IC), i.e., RLT FTR/antipyrine FTR, was 0.28 ± 0.05. In the fetal-to-maternal direction, the mean ± SD CI was 0.31 ± 0.09. Placental transfer of RLT was high in both directions.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research